Loading...

RARE ULTRAGENYX PHARMACEUTICAL INC Expansion Plans 8-K Filing

LTRG

RR

ULTRAGENYX PHARMACEUTICAL INC

(RARE)

2025 8-K

Royalty Agreement Signed

Patient Dosing Initiated

Positive DTX401 Results

FDA Application Start

Financial Statements

Product Expansion

Pre-Market Approval

Clinical Trials

Pre-Market Approval

Earnings Releases

Financial Results

FDA Application

Financial Results

FDA Designation

UX701 Study Update

Earnings Reports

FDA Meeting for Phase 3 Stu...

Annual Meeting and Election...

Public Offering

FDA Meeting for UX111 Gene ...

Phase 2/3 Orbit Study Results

Positive Phase 3 Results fo...

Financial Results Announcement

New Data from Phase 1/2 Stu...

Earnings Reports

Earnings Reports

Bylaws Amendment

Earnings Reports

Underwriting Agreement for ...

Pipeline Updates

Appointment Change

Financial Results Announcement

Annual Meeting Approval

Phase 2 Orbit study data an...

FDA Protocol Amendment

Earnings Report

Departure of Directors or C...

Financial Results Announcement

Earnings Reports

External Links:

On July 31, 2025, Ultragenyx Pharmaceutical Inc. announced that their Phase 3 Aspire study for GTX-102, a treatment for Angelman Syndrome, is fully enrolled with 129 participants. The study aims to assess cognitive improvements and is expected to complete in the second half of 2026.

AI Assistant

ULTRAGENYX PHARMACEUTICAL INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.